Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2012

01-09-2012 | Letter to the Editor

Sequential therapy in metastatic renal cell carcinoma: what comes next?

Authors: Camillo Porta, Thomas Powles

Published in: Medical Oncology | Issue 3/2012

Login to get access

Excerpt

Metastatic renal cell carcinoma (mRCC) is a fast-moving therapeutic field with multiple targeted agents approved and many more in development. In our expert agreement article [1], we evaluated available data together with our clinical experience to consider how we might optimize using targeted therapies in sequence, emphasizing the need continually to address the question, “what comes next?” Crucially, new phase III data presented at the American Society of Clinical Oncology (ASCO) 2011 annual meeting provide level 1 evidence that patients can receive continued clinical benefit when VEGF-targeted tyrosine kinase inhibitors (TKIs) are used sequentially [2, 3]. …
Literature
1.
Porta C, et al. Maximizing the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol. 2011; E-pub ahead of print.
2.
3.
4.
Al-Marrawi MY, et al. The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). J Clin Oncol. 2011 (abstract 4555).
5.
Porta C, et al. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010;36(1):16–23.PubMedCrossRef
Metadata
Title
Sequential therapy in metastatic renal cell carcinoma: what comes next?
Authors
Camillo Porta
Thomas Powles
Publication date
01-09-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-0073-z

Other articles of this Issue 3/2012

Medical Oncology 3/2012 Go to the issue

Original Paper

Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine

Original Paper

Urban and non-urban disparities in the use of post-mastectomy radiation for breast cancer

Original Paper

Unexpected effect of the monoclonal antibody Panitumumab on human cancer cells with different KRAS status

Case Report

Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen

Original Paper

A novel prognostic model for extranodal natural killer/T-cell lymphoma

Original Paper

Girdin protein: a new potential distant metastasis predictor of breast cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits